Arlington Financial Advisors LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 6.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,147 shares of the company’s stock after selling 80 shares during the quarter. Arlington Financial Advisors LLC’s holdings in Johnson & Johnson were worth $203,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently bought and sold shares of the company. Veracity Capital LLC increased its holdings in Johnson & Johnson by 1.2% during the 4th quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock worth $888,000 after acquiring an additional 59 shares during the period. Sandy Cove Advisors LLC increased its holdings in shares of Johnson & Johnson by 1.6% in the 3rd quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock worth $605,000 after buying an additional 60 shares during the last quarter. Paces Ferry Wealth Advisors LLC increased its holdings in shares of Johnson & Johnson by 0.7% in the 3rd quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock worth $1,425,000 after buying an additional 62 shares during the last quarter. Mason & Associates Inc increased its holdings in shares of Johnson & Johnson by 4.9% in the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock worth $215,000 after buying an additional 62 shares during the last quarter. Finally, Magnolia Capital Advisors LLC increased its holdings in shares of Johnson & Johnson by 0.7% in the 3rd quarter. Magnolia Capital Advisors LLC now owns 8,883 shares of the company’s stock worth $1,451,000 after buying an additional 62 shares during the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at Johnson & Johnson
In other news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.35% of the company’s stock.
Johnson & Johnson Trading Down 1.0 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.22 by $0.13. The business had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The firm’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.13 EPS. On average, research analysts anticipate that Johnson & Johnson will post 10.5 EPS for the current year.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were given a $1.13 dividend. The ex-dividend date was Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.98%. Johnson & Johnson’s dividend payout ratio is 67.06%.
Analyst Upgrades and Downgrades
JNJ has been the topic of a number of research analyst reports. Atlantic Securities increased their price target on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a report on Wednesday, January 25th. Guggenheim initiated coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target on the stock. Piper Sandler decreased their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 1st. Finally, Citigroup increased their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Eight research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.73.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?
- Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
- Meta Breaks Out Of A Base, Looks Like A Growth Stock Again
- The Bottom Is In For McCormick & Company
- Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
